Cancer's ability to hide from immune surveillance may have found a new villain in Hodgkin lymphoma, where malignant cells appear to have mastered an elaborate disappearing act that shields them from natural killer cell detection. This discovery could reshape how oncologists approach one of the most treatable blood cancers.
RNA sequencing of Hodgkin and Reed-Sternberg cells from eighteen primary tumors revealed these cancer cells systematically suppress B cell identity markers while downregulating SLAM family ligands like CD48—molecular flags that normally alert NK cells to eliminate abnormal cells. Simultaneously, the malignant cells activate an unfolded protein response pathway typically seen in multiple myeloma, suggesting they're attempting a failed transformation into plasma cells while maintaining their cancerous state.
The transcriptomic analysis positioned these findings within the broader landscape of B cell malignancies, where immune evasion strategies vary dramatically between cancer types. Unlike primary mediastinal B cell lymphoma, which shares genetic mutations with Hodgkin lymphoma but maintains different immune profiles, Hodgkin lymphoma cells appear uniquely skilled at erasing their cellular identity markers. This molecular camouflage represents a sophisticated evolution beyond simple oncogene activation.
While Hodgkin lymphoma already enjoys high cure rates with current therapies, understanding these evasion mechanisms could prove crucial for the minority of patients who relapse or develop treatment resistance. The identification of specific immune checkpoint failures opens potential avenues for NK cell-based immunotherapies or targeted interventions that restore proper immune recognition signals.